Design and created by Guideline Central in participation with the American Society of Addiction Medicine.
American Society of Addiction Medicine
Publication Date: November 7, 2022
| Medicación | Nombres comerciales |
|---|---|
| Buprenorfina | Sublocade® (inyectable), Brixadi® (inyectable), Probuphine® (implantable), genéricos (comprimidos o comprimidos recubiertos) |
| Buprenorfina y naloxona | Bunavail®, Cassipa®, Suboxone®, Zubsolv®, genéricos (comprimidos o comprimidos recubiertos) |
| Metadona | genéricos (líquidos o comprimidos para disolver en agua) |
| Naltrexona de liberación prolongada | Vivitrol® (inyectable) |
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. Available at: https://www.asam.org/Quality-Science/quality/ 2020-national-practice-guideline. doi: 10.1097/ADM.0000000000000633
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.